Nouvelles

Developing a Potent Microtubule-Targeting Agent with Less Toxicity

Diazon Pharmaceuticals is developing DZ-2384, which targets a proven therapeutic pathway in oncology, but with less toxicity than existing agents, as demonstrated in a preclinical study published November 2016 in Science Translational Medicine by researchers at McGill University in Canada.

Microtubule-Straightening Compound Widens the Therapeutic Window

Reporting in Science Translational Medicine, Brouhard, Roulston and colleagues present a novel small-molecule MTA that has potent antitumour activity in several different cancer models.

Novel microtubule-targeting agent largely avoids neuropathy

In cancer therapy, chemotherapy is the workhorse to immunooncology’s and targeted therapy’s show horses. “There has not been a lot of innovation” in the area of chemotherapy, Gordon Shore told BioWorld Insight. Partly, he said, there are good reasons for the attention lavished on immuno-oncology and targeted therapies. The pathways targeted by those approaches “are where the underlying biology of cancer lies, and where rational intervention makes a lot of sense.” But chemotherapies remain both a market opportunity and an area in need of innovation.

THE SYNTHETIC DIAZONAMIDE DZ-2384 HAS DISTINCT EFFECTS ON MICROTUBULE CURVATURE AND DYNAMICS WITHOUT NEUROTOXICITY

The synthetic diazonamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicity, Science Translational Medicine, 2016 Nov 16;8(365):365ra159. For complete article see www.ltdmcgill.ca under “Publications”.